This Phase III trial known as ZEST is designed to assess the efficacy of vandetanib versus erlotinib in overall survival and progression-free survival in over 1,150 patients with locally advanced or metastatic non-small cell lung cancer after failure of first-line anticancer therapy. ZEST is part of a Phase III clinical trial program to gain a broad understanding of how vandetanib may benefit people with lung cancer.
Peter Langmuir, medical science director at AstraZeneca, said: “Non-small cell lung cancer is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option for people with lung cancer.”